Evaluation of the KLOX BioPhotonic OraLum Gel With a LED Curing Lamp in Moderate to Severe Chronic Periodontitis
NCT ID: NCT02325570
Last Updated: 2016-02-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
30 participants
INTERVENTIONAL
2014-11-30
2015-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of the Efficacy and Safety of OROXID® Oral Solution in Patients With Periodontitis
NCT07257887
Home Use of Dual-light Photodynamic Therapy for Chronic Periodontitis
NCT05425784
Photobiomodulation and Platelets Rich in Growth Factors (PRGFs)-Assisted Flap Surgery in Treating Stage III Periodontal Defects
NCT06641739
Diode Laser-Assisted Periodontal Therapy Enhances Clinical Outcomes for Deep Periodontal Pockets in Smokers
NCT07213752
Periocline as an Adjunct to Scaling and Root Planing for Adult Periodontitis
NCT00529555
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
KLOX BioPhotonic OraLum Gel + SRP
Split-mouth design:the half-mouth randomly selected will be treated with KLOX BioPhotonic OraLum gel (with a LED curing lamp) as an adjunct to SRP.
KLOX BioPhotonic OraLum Gel
Klox BioPhotonic OraLum Gel will be used with a LED curing lamp as an adjunct to conventional non-surgical periodontal treatment (SRP).
Scaling and Root Planing (SRP)
Scaling and Root Planing (SRP) is the conventional non-surgical treatment of chronic periodontitis.
Scaling and Root Planing (SRP)
The second half-mouth will be treated with SRP alone.
Scaling and Root Planing (SRP)
Scaling and Root Planing (SRP) is the conventional non-surgical treatment of chronic periodontitis.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
KLOX BioPhotonic OraLum Gel
Klox BioPhotonic OraLum Gel will be used with a LED curing lamp as an adjunct to conventional non-surgical periodontal treatment (SRP).
Scaling and Root Planing (SRP)
Scaling and Root Planing (SRP) is the conventional non-surgical treatment of chronic periodontitis.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Male or female patients aged 18 years old and above;
3. Good general health, free of systemic diseases such as diabetes, arthritis, HIV infection or genetic disorder that could influence the outcome of the treatment;
4. Patient with clinically confirmed signs and symptoms of generalized moderate to severe chronic periodontitis (as defined according to International Classification of Periodontal Diseases, Armitage 1999);
5. Patient has had no periodontal treatment for the last year prior to the study;
6. Females of childbearing potential must not be pregnant nor lactating at study entry and agree to use an adequate contraceptive method during the study.
7. Patient demonstrates sufficient plaque control as indicated by a plaque score \< 30% after hygiene period;
8. Patient has at least two sites in each quadrant with probing pocket depth (PPD) equal or more than 5 mm or equal or less than 7 mm.
Exclusion Criteria
2. Presence of oral local mechanical factor(s) that could, in the opinion of the investigator, influence the outcome of the study;
3. Presence of orthodontic appliances, or any removable appliances, that impinges on the tissues being assessed;
4. Soft or hard tissue tumours of the oral cavity;
5. Systemic antibiotic therapy or anti-inflammatory drugs or any other medication(s) that might interfere with periodontal healing within the last three months prior to study entry and throughout the study duration;
6. Patient has participated in any other clinical study within 30 days prior to study entry and throughout the study duration;
7. Use of anticoagulants such as warfarin, clopidogrel, enoxaparin or high doses of aspirin (162 mg daily);
8. Regular use of chlorhexidine oral rinses / mouthwashes (Non-medicated, over the counter, mouthwashes are acceptable);
9. Patient with current alcohol abuse or actively consuming drugs (addiction); as it may interfere with patient's ability to comply with study procedures
10. Periodontal surgery planned during the study;
11. Female patient pregnant, nursing or planning to become pregnant within the next 12 months;
12. Patient is a current smoker or had been smoking or using nicotine product(s) in the last six months;
13. Concurrent disease (such as porphyria) or drug(s) (such as methotrexate or chloroquine) known to induce severe photosensitivity of the skin;
14. Patient has ongoing malignant disease of any type, or any significant chronic disease which, in the opinion of the investigator, might interfere with the evaluation of the study objectives or would result in non-compliance with the study protocol;
15. Patients with known hypersensitivity to peroxide;
16. Patients with known photosensitivity or who take drugs to treat photosensitivity.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
KLOX Technologies Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anthony Seminara, DDM
Role: PRINCIPAL_INVESTIGATOR
Dr. Anthony Seminara Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dr. Anthony Seminara Inc.
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CL-K1004-P001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.